A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis

BACKGROUND: Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently being investigated as a treatment for anemia of chronic kidney disease (CKD) in both dialysis and nondialysis patients. In clinical studies to date, daprodustat has been administered orally as a once-daily r...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailey, Christine K., Caltabiano, Stephen, Cobitz, Alexander R., Huang, Chun, Mahar, Kelly M., Patel, Vickas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796426/
https://www.ncbi.nlm.nih.gov/pubmed/31619187
http://dx.doi.org/10.1186/s12882-019-1547-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796426/
https://www.ncbi.nlm.nih.gov/pubmed/31619187
http://dx.doi.org/10.1186/s12882-019-1547-z

Ejemplares similares